Analysis of the Effectiveness of Oral Antidiabetic Therapy on HbA1c Control in Type 2 Diabetes Mellitus Patients
Analisis Efektivitas Terapi Antidiabetes Oral terhadap Pengendalian Kadar HbA1c pada Pasien Diabetes Mellitus Tipe 2
DOI:
https://doi.org/10.53342/pharmasci.v11i2.595Keywords:
Diabetes Mellitus tipe 2,, HbA1c,, Antidiabetes oral,, Efektivitas terapi,Abstract
Effective glycemic control is crucial for preventing chronic complications in patients with type 2 diabetes mellitus (T2DM). HbA1c levels are one of the best indicators that can be used to evaluate the success of pharmacological therapy in the long term. The purpose of this study was to analyze the effectiveness of oral antidiabetic use in reducing HbA1c levels in T2DM patients. This study used an observational quasi-experimental design with a one-group pre-post test approach conducted on 100 respondents. Statistical analysis used a paired sample t-test with a significance level of 95% (? = 0.05). The data used included demographic profiles and HbA1c levels before and after oral antidiabetic therapy intervention. The results showed that the average HbA1c level before therapy was 6.85 ± 1.54%, while after therapy it became 6.40 ± 1.22%. There was a decrease in the average HbA1c by 0.45%. The results of the Paired Sample t-Test showed a p value = 0.002 (p < 0.05), indicating a significant difference between HbA1c levels before and after therapy. In addition, the proportion of patients with poorly controlled HbA1c decreased from 15% to 5% after therapy. The conclusion of this study is that a significant decrease in HbA1c levels indicates that oral antidiabetic therapy can help achieve glycemic control targets and potentially reduce the risk of long-term diabetes complications.
References
1. Abdulbari Bener FM. Projection of Diabetes Burden through 2025 and Contributing Risk Factors of Changing Disease Prevalence: An Emerging Public Health Problem. J Diabetes Metab. 2024;05(02).
2. Care D, Suppl SS. 2 . Diagnosis and Classification of Diabetes : Standards of Care in Diabetes — 2024. 2024;47(January):20–42.
3. Roglic G. Review Article WHO Global report on diabetes : A summary. 2023;3–8.
4. Dipiro JT, Tee GC, Haines ST, Nolin TD, Ellingrod V., Posey LM. Dipiro’S Pharmacotherapy a Pathophysiologic Approach 12Th Edition. 2023.
5. December EU, Sayed N El. News Release. Am Diabetes Assoc. 2025;2024–6.
6. Teufel F, Orgutsova K, Genitsaridi I, Carrillo-larco RM, Varghese JS, Marcus ME, et al. Diabetes in Adults : Findings From the 2025 IDF Diabetes Atlas Global , Regional , and National Estimates of Undiagnosed Diabetes in Adults : Findings From the 2025 IDF Diabetes Atlas. 2026;
7. Ong KL. Global , regional , and national burden of diabetes from 1990 to 2021 , with projections of prevalence to 2050 : a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2025;
8. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications : a review of current evidence. Diabetologia. 2019;3–16.
9. IDF Diabetes Atlas. 2025.
10. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Consensus Report by the American Diabetes Association ( ADA ) and the European Association for the Study of Diabetes ( EASD ) Management of Hyperglycemia in Type 2 Diabetes , 2022 . A Consensus Report by the American Diabetes Association ( ADA ) and the European Association for the Study of Diabetes ( EASD ). 2022;45(11):2753–86.
11. American Diabetes Association Professional Practice Committee. Cardiovascular Disease and Risk Management : Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(January):179–218.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Chinthia Devientasari, Selly Septi Fandinata, Dini Berliana, Anggi Restyana, Luluk Aniqoh Meliana Putri, Devita Riafinola Andaririt
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
